144 Results
Sort By:
Published on December 13, 2023
An international study has shown that Hodgkin lymphoma recurrence and drug response can be predicted using the levels of circulating tumor DNA (ctDNA) in a patient’s blood. The Stanford Medicine-led research, reported in Nature, examined hundreds of samples from patients with classic Hodgkin lymphoma (cHL) and suggests that profiling using…
Published on April 10, 2023
Sponsored content brought to you by When it comes to developing new cancer therapeutics, time is of the essence—for the patients that need treatments most, every day counts. Traditional benchmarks for evaluating a treatment’s effectiveness in clinical trials, such as five-year survival rates, deliver prognostic insights on a slower timeline…
Published on March 20, 2023
Oxford Nanopore Technologies and Dutch start-up Cyclomics have announced “developer access” to a new research workflow they call “the world’s first nanopore sequencing-based solution for ultra-sensitive detection of circulating tumor DNA (ctDNA).” The system works by detecting and analyzing cell-free DNA (cfDNA) in the blood stream. As tumor cells die,…
Published on June 8, 2022
A new research study led by scientists at the Johns Hopkins Kimmel Cancer Center and WEHI demonstrates that circulating tumor DNA (ctDNA) can identify stage II colon cancer patients who can most benefit from chemotherapy following surgery. The findings are published in the New England Journal of Medicine in a paper titled…
Published on September 13, 2021
Pre-treatment circulating tumor (ct)DNA levels may more accurately predict long-term survival than classical survival surrogates and might be useful for the design of new clinical trials, according to research presented on the Neo-Adjuvant Immunotherapy Study (NADIM) at the recent IASLC 2021 World Conference on Lung Cancer. There are currently no…
Published on August 4, 2020
Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto. The scientists also tested whether changes in ctDNA during treatment could reflect whether patients would have…
Published on April 30, 2020
A study using a single mutation-based screening blood test for multiple cancer types found it could detect asymptomatic cancers in women. In the Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A) study, 10,000 women ages 65 to 75 with no prior cancer history were evaluated using CancerSEEK,…
Published on January 3, 2020
Circulating tumor DNA (ctDNA), which is DNA that has been shed from ruptured cancer cells into the patient’s bloodstream, has quickly emerged as a useful biomarker for numerous cancer types. Liquid assays have been developed to use ctDNA as a reliable, non-intrusive technique to assess the genetic mutations for some…
Published on April 19, 2019
Genomics England said it has generated positive results from the first phase of a collaboration with Inivata and Thermo Fisher Scientific designed to study the use of liquid biopsies in cancer. The study demonstrated what the agency overseeing the 100,000 Genomes Project said was “the strong potential for liquid biopsy…
Published on March 29, 2019
Molecular diagnostic company ArcherDX announced it has entered into a research collaboration with the University College London (UCL) and the Francis Crick Institute to use ArcherDX’s proprietary Anchored Multiplex PCR (AMP) technology to detect evidence of disease recurrence in lung cancer patients using cell-free circulating tumor DNA (ctDNA). The research…
Published on January 28, 2019
Molecular diagnostics company Biocept has launched the first in what will be a series of liquid biopsy test kits for cancer with the intention of increasing the use of its Target Selector ctDNA testing platform. The first kit, available for research-use-only (RUO), is for the detection of the EGFR oncogene…
Published on September 14, 2018
Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). Under the collaboration, whose value was not disclosed, BMS will use…
Published on December 20, 2016
Investigators from Sorbonne University in Paris have now assessed the feasibility and the prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma, a significant advance in a hard-to-diagnose disease that is expected to become the second leading cause of cancer death in the U.S. by 2030. There remain several…
Published on February 6, 2024
Comprehensive genomic profiling (CGP) is ushering in an era of precision medicine by making it easier to treat tumors in a targeted manner. Check out 10 leading specialists providing these game-changing services. As increasingly targeted cancer treatments enter the market, demand is growing for ways to quickly learn which patients…
Published on January 24, 2024
A team of researchers from MIT and the Broad Institute of MIT and Harvard have established a way to significantly boost the sensitivity of liquid biopsies by delaying the clearance of circulating tumor (ct)DNA from the blood. They have developed two different types of injectable priming agents that transiently interfere…